CUSIP: 74140Y101
Q2 2020 13F Holders as of 30 Jun 2020
-
Type / Class
-
Equity / COM
-
Total 13F shares
-
28,255,298
-
Share change
-
+439,309
-
Total reported value
-
$421,003,288
-
Price per share
-
$14.90
-
Number of holders
-
65
-
Value change
-
+$7,892,147
-
Number of buys
-
39
-
Number of sells
-
17
Quarterly Holders Quick Answers
What is CUSIP 74140Y101?
CUSIP 74140Y101 identifies PRVL - PREVAIL THERAPEUTICS INC - COM in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
-
Newer quarter:
Q3 2020
-
Previous quarter:
Q1 2020
Recent filing periods for CUSIP 74140Y101:
Institutional Holders of PREVAIL THERAPEUTICS INC - COM (PRVL) as of Q2 2020
As of 30 Jun 2020,
PREVAIL THERAPEUTICS INC - COM (PRVL) was held by
65 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
28,255,298 shares.
The largest 10 holders included
ORBIMED ADVISORS LLC, RA CAPITAL MANAGEMENT, L.P., BlackRock Inc., ADAGE CAPITAL PARTNERS GP, L.L.C., CITADEL ADVISORS LLC, BOXER CAPITAL, LLC, Avidity Partners Management LP, FMR LLC, VANGUARD GROUP INC, and Artal Group S.A..
This page lists
65
institutional shareholders reporting positions in this security
for the Q2 2020 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.